Details

Autor(en) / Beteiligte

• Nissen, Steven E
• Yeomans, Neville D
• Solomon, Daniel H
• Lüscher, Thomas F
• Libby, Peter
• Husni, M. Elaine
• Graham, David Y
• Borer, Jeffrey S
• Wisniewski, Lisa M
• Wolski, Katherine E
• Wang, Qiuqing
• Menon, Venu
• Ruschitzka, Frank
• Gaffney, Michael
• Beckerman, Bruce
• Berger, Manuela F
• Bao, Weihang
• Lincoff, A. Michael

Titel

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis

Ist Teil von

• The New England journal of medicine, 2016-12, Vol.375 (26), p.2519-2529

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• This randomized trial involving patients with osteoarthritis or rheumatoid arthritis who were at increased cardiovascular risk showed the noninferiority of celecoxib to naproxen or ibuprofen with respect to cardiovascular safety. Nonsteroidal antiinflammatory drugs (NSAIDs) were introduced in the 1960s and became the most widely prescribed class of drugs in the world, with more than 100 million prescriptions issued annually in the United States alone. 1 NSAIDs inhibit cyclooxygenase (COX), which reduces pain and inflammation through the inhibition of prostaglandins. However, the COX enzyme is also present in gastric mucosa, where it stimulates gastroprotective prostaglandins. The identification of two isoforms, COX-1 and COX-2, and the recognition that antiinflammatory and analgesic effects are mediated through COX-2 inhibition — whereas the gastrointestinal toxic effects are linked to COX-1 inhibition — resulted in the development . . .